FDA IMPORT SEIZURE AUTHORITY CHALLENGED
Executive Summary
FDA IMPORT SEIZURE AUTHORITY CHALLENGED in an April 18 decision by a New Orleans federal judge that the agency was required to give an importer the opportunity to export mushrooms thought to be misbranded or adulterated before seizing them. The decision could affect other FDA-regulated products such as drugs, cosmetics and devices. The importer claims it has the right to re- export the products because they had not cleared customs at the time they were seized.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth